Concepedia

Mihály Hajós

MH

Statistics

Publications

98

Citations

6.9K

H-Index

45

Active since

1981

Affiliations

Pfizer (United States)(Current)

Yale University

University of Oxford

University of Szeged

Harvard University

Mihály Hajós is an author at Pfizer (United States) specializing in medicine, neuroscience, and neurophysiology.

ORCID

Top concepts

Publications per year

1981–2025

98

Publications

98

A Novel Positive Allosteric Modulator of the α7 Neuronal Nicotinic Acetylcholine Receptor:<i>In Vitro</i>and<i>In Vivo</i>Characterization

Raymond S Hurst, Mihály Hajós, M. Raggenbass et al. · Journal of Neuroscience · 2005 · 441 citations · Full text

, , +18

Interaction between a selective 5‐HT<sub>1A</sub>receptor antagonist and an SSRI in vivo: effects on 5‐HT cell firing and extracellular 5‐HT

Sarah E. Gartside, Valerie Umbers, Mihály Hajós et al. · British Journal of Pharmacology · 1995 · 311 citations · Full text

An electrophysiological and neuroanatomical study of the medial prefrontal cortical projection to the midbrain raphe nuclei in the rat

Mihály Hajós, Carl D. Richards, Andrea Székely et al. · Neuroscience · 1998 · 303 citations

, , +10

Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

C J Schmidt, Douglas S. Chapin, J. Cianfrogna et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 284 citations

The Selective α7 Nicotinic Acetylcholine Receptor Agonist PNU-282987 [N-[(3 R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide Hydrochloride] Enhances GABAergic Synaptic Activity in Brain Slices and Restores Auditory Gating Deficits in Anesthetized Rats

Mihály Hajós, Raymond S Hurst, William E. Hoffmann et al. · Journal of Pharmacology and Experimental Therapeutics · 2005 · 223 citations

Rows per page

1–5 of 98